HCAT Stock Overview
Provides data and analytics technology and services to healthcare organizations in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Health Catalyst, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.36 |
| 52 Week High | US$11.41 |
| 52 Week Low | US$5.42 |
| Beta | 1.32 |
| 11 Month Change | -14.42% |
| 3 Month Change | 4.25% |
| 1 Year Change | -4.66% |
| 33 Year Change | -83.64% |
| 5 Year Change | -80.36% |
| Change since IPO | -81.21% |
Recent News & Updates
Recent updates
Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets
Sep 24Health Catalyst, Inc.'s (NASDAQ:HCAT) Shares Lagging The Industry But So Is The Business
Jul 17
Health Catalyst: Stellar Earnings Growth Projected
Jun 26Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price
Apr 04Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible
Mar 09Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade)
Feb 16Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?
Jan 27What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You
Dec 24Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?
Dec 15Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?
Oct 24Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price
Jul 31Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Jun 27Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Feb 22Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate
Dec 06Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?
Nov 03Health Catalyst: Looking For A Turnaround For This 'Bio Boom' Candidate
Oct 14Health Catalyst names Kevin Freeman as Chief Growth Officer, Tarah Bryan as Chief Marketing Officer, Dave Ross as Chief Technology Officer
Sep 07Shareholder Returns
| HCAT | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -15.0% | -8.3% | -1.0% |
| 1Y | -4.7% | 5.7% | 30.3% |
Return vs Industry: HCAT underperformed the US Healthcare Services industry which returned 7.1% over the past year.
Return vs Market: HCAT underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| HCAT volatility | |
|---|---|
| HCAT Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HCAT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HCAT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,300 | Dan Burton | www.healthcatalyst.com |
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Health Catalyst, Inc. Fundamentals Summary
| HCAT fundamental statistics | |
|---|---|
| Market cap | US$458.79m |
| Earnings (TTM) | -US$79.14m |
| Revenue (TTM) | US$302.06m |
1.5x
P/S Ratio-5.7x
P/E RatioIs HCAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCAT income statement (TTM) | |
|---|---|
| Revenue | US$302.06m |
| Cost of Revenue | US$162.59m |
| Gross Profit | US$139.47m |
| Other Expenses | US$218.61m |
| Earnings | -US$79.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 46.17% |
| Net Profit Margin | -26.20% |
| Debt/Equity Ratio | 97.2% |
How did HCAT perform over the long term?
See historical performance and comparison